TBS 5
Alternative Names: Asthma maintenance therapy - Acerus Pharmaceuticals; TBS-5Latest Information Update: 17 May 2016
Price :
$50 *
At a glance
- Originator Trimel Pharmaceuticals Corporation
- Developer Acerus Pharmaceuticals Corporation
- Class Corticosteroids
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Asthma
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
- 04 Mar 2015 Preclinical development is ongoing in Canada
- 04 Mar 2015 TBS 5 is available for licensing as of 04 Mar 2015. http://trimelpharmaceuticals.com/